<p>2025 年 11 月 08 日- 下午 02:30</p>
<p><strong>口头报告强调了 sotagliflozin 对 HFpEF 患者在显著改善心脏和身体表现以及生活质量方面的独特益处</strong></p>
<p>德克萨斯州伍德兰，2025 年 11 月 08 日（GLOBE NEWSWIRE）-- Lexicon Pharmaceuticals, Inc.（纳斯达克：LXRX）今天宣布，在 2025 年美国心脏协会年会科学会议上展示了新的 sotagliflozin 临床数据。数据突出了 sotagliflozin 治疗在心脏功能保留射血分数（HFpEF）且无糖尿病的心力衰竭患者中观察到的益处，涵盖了心脏结构和功能、生活质量和功能能力等多个指标。</p>
<p>该研究在纽约市西奈山医疗中心的动脉血栓研究单位主任、医学/心脏病学教授 Juan J Badimon 博士的指导下进行，名为 “SOTA P CARDIA：无糖尿病 HFpEF 患者的 sotagliflozin 随机试验”，是一项前瞻性、随机、双盲、安慰剂对照试验，专门招募 HFpEF 患者，这是心力衰竭中增长最快的形式。</p>
<p>该研究的目的是比较 sotagliflozin 与安慰剂在多个心脏功能和结构指标上的治疗效果，例如左心室质量、舒张功能、标准六分钟步行测试和 KCCQ。研究招募了 88 名参与者，种族多样性，70% 为女性。患者接受 sotagliflozin 或安慰剂治疗六个月，并在治疗期间及结束后进行组间比较。</p>
<p>sotagliflozin 治疗导致左心室质量、舒张功能、六分钟步行测试能力和 KCCQ 测量的统计学显著改善。此外，尽管峰值 VO2 的改善未达到统计学显著性，但在 sotagliflozin 治疗后有明显改善。</p>
<p>“在研究中观察到的 sotagliflozin 治疗的益处包括心脏结构和功能的显著改善、症状缓解，以及最重要的生活质量和功能能力的提升，” Badimon 博士表示。“尽管 sotagliflozin 在两年前已获批用于有或无糖尿病的心力衰竭患者，但我们的研究是首个证明对无糖尿病的保留射血分数患者具有重要临床益处的研究。”</p>
<p>根据美国心脏病学会的数据显示，近 670 万美国人患有心力衰竭，其中超过一半为保留射血分数。这种情况通常导致频繁住院，且一年死亡风险约为 25%。</p>
<p>“当你将这些研究结果与之前报告的 sotagliflozin 治疗患者在急性心力衰竭事件后再住院和 MACE 风险降低的数据结合起来时，sotagliflozin 被视为一种不同类别药物的潜力开始显现，” Lexicon 的高级副总裁兼首席医学官 Craig Granowitz 博士表示。</p>
<p>点击此处并搜索 “SOTA P CARDIA” 以访问研究摘要。</p>
<p><strong>关于 Sotagliflozin</strong></p>
<p>sotagliflozin 是通过 Lexicon 独特的基因科学方法发现的，是一种口服抑制剂，针对两种负责葡萄糖调节的蛋白质，即钠 - 葡萄糖共转运蛋白 2 型和 1 型（SGLT2 和 SGLT1）。SGLT2 负责肾脏对葡萄糖和钠的重吸收，而 SGLT1 负责胃肠道对葡萄糖和钠的吸收。sotagliflozin 已在多个患者群体中进行研究，包括心力衰竭、糖尿病和慢性肾病，临床研究涉及约 20,000 名患者。sotagliflozin 目前也在研究另一种心脏疾病，肥厚型心肌病（HCM）。</p>
<p><strong>关于 Lexicon Pharmaceuticals</strong></p>
<p>Lexicon 是一家生物制药公司，致力于开创改变患者生活的药物。通过 Genome5000™计划，Lexicon 独特的基因组靶点发现平台，Lexicon 科学家研究了近 5,000 个基因的作用和功能，并识别出 100 多个在多种疾病中具有显著治疗潜力的蛋白质靶点。通过对这些蛋白质的精确靶向，Lexicon 正在开创安全有效治疗疾病的创新药物的发现和开发。Lexicon 在神经性疼痛、HCM、肥胖、代谢及其他适应症方面拥有一系列有前景的药物候选者，处于发现、临床和临床前开发阶段。有关更多信息，请访问 www.lexpharma.com。</p>
<p><strong>安全港声明</strong></p>
<p>本新闻稿包含 “前瞻性声明”，包括与 Lexicon 的财务状况和长期业务前景相关的声明，包括其已批准产品的商业化以及 sotagliflozin 及其其他药物候选者的临床开发、监管申请和潜在治疗及商业潜力。此外，本新闻稿还包含与 Lexicon 的增长和未来运营结果、产品的发现、开发和商业化、战略联盟和知识产权相关的前瞻性声明，以及其他非历史事实或信息的事项。所有前瞻性声明均基于管理层当前的假设和预期，并涉及风险、不确定性和其他重要因素，特别包括 Lexicon 满足其资本需求的能力、成功商业化其已批准产品的能力、成功进行临床前和临床开发并在预期时间内获得其他药物候选者的必要监管批准的能力、实现其运营目标、为其发现获得专利保护以及建立战略联盟的能力，以及与制造、知识产权和其已批准产品及其他药物候选者的治疗或商业价值相关的其他因素。这些风险、不确定性和其他因素可能导致 Lexicon 的实际结果与任何前瞻性声明所表达或暗示的未来结果存在重大差异。识别这些重要因素的信息包含在 Lexicon 截至 2024 年 12 月 31 日的年度报告 Form 10-K 中的 “风险因素” 部分，该报告已提交给证券交易委员会。Lexicon 没有义务更新或修订任何此类前瞻性声明，无论是由于新信息、未来事件还是其他原因。</p>
<p><strong>投资者和媒体咨询</strong>：</p>
<p>Lisa DeFrancesco</p>
<p>Lexicon Pharmaceuticals, Inc.</p>
<p>lexinvest@lexpharma.com</p>
<p><img src="https://imageproxy.pbkrs.com/https://www.globenewswire.com/newsroom/ti/query-bmY9T1RVM01UZzNNeU0zTWpVek1EZ3lJekl3TURNNU5qYz0?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.globenewswire.com/newsroom/ti/query-bmY9T1RVM01UZzNNeU0zTWpVek1EZ3lJekl3TURNNU5qYz0"/></p>
<p><img src="https://imageproxy.pbkrs.com/https://ml.globenewswire.com/media/ZmM1YzI3ODQtOTI3OS00NDYzLTk4OTEtNTllNjk2ZjFlODliLTEwMTU1NDAtMjAyNS0xMS0wOC1lbg==/tiny/Lexicon-Pharmaceuticals-Inc-.png?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://ml.globenewswire.com/media/ZmM1YzI3ODQtOTI3OS00NDYzLTk4OTEtNTllNjk2ZjFlODliLTEwMTU1NDAtMjAyNS0xMS0wOC1lbg==/tiny/Lexicon-Pharmaceuticals-Inc-.png"/></p>

莱斯康制药

<p>莱斯康制药在 2025 年美国心脏协会年会科学会议上展示了关于 sotagliflozin 的新临床数据，强调其在改善心力衰竭患者（保留射血分数 HFpEF 且无糖尿病）的心脏功能和生活质量方面的疗效。该研究由胡安·J·巴迪蒙博士领导，涉及 88 名参与者，结果显示经过六个月的治疗后，心脏结构、功能和功能能力显著改善。Sotagliflozin 是一种口服 SGLT2 和 SGLT1 抑制剂，正在针对其他心脏疾病进行研究。莱斯康的目标是通过其基因组靶点发现平台开创创新药物</p>

<p>11/08/2025 - 02:30 PM</p>
<div class="lb-trans"><p>2025 年 11 月 08 日- 下午 02:30</p>
</div><p><strong>Oral presentation highlights sotagliflozin's unique benefits to HFpEF patients in significantly improving cardiac and physical performance, and quality of life</strong></p>
<div class="lb-trans"><p><strong>口头报告强调了 sotagliflozin 对 HFpEF 患者在显著改善心脏和身体表现以及生活质量方面的独特益处</strong></p>
</div><p>THE WOODLANDS, Texas, Nov. 08, 2025 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced that new sotagliflozin clinical data was presented at the AHA Annual Scientific Sessions 2025. The data highlighted benefits observed from sotagliflozin treatment in heart failure patients with preserved ejection fraction (HFpEF), and without diabetes, across a range of measures, including cardiac structure and function, quality of life and functional capacity.</p>
<div class="lb-trans"><p>德克萨斯州伍德兰，2025 年 11 月 08 日（GLOBE NEWSWIRE）-- Lexicon Pharmaceuticals, Inc.（纳斯达克：LXRX）今天宣布，在 2025 年美国心脏协会年会科学会议上展示了新的 sotagliflozin 临床数据。数据突出了 sotagliflozin 治疗在心脏功能保留射血分数（HFpEF）且无糖尿病的心力衰竭患者中观察到的益处，涵盖了心脏结构和功能、生活质量和功能能力等多个指标。</p>
</div><p>Conducted under the direction of Dr. Juan J Badimon, PhD, FACC, FAHA, director, Atherothrombosis Research Unit, professor of Medicine/Cardiology at Mount Sinai Medical Center in New York City, “SOTA P CARDIA: A Randomized Trial of Sotagliflozin in HFpEF Patients without Diabetes” was a prospective, randomized, double-blind, placebo-controlled trial that exclusively enrolled patients with HFpEF, the most rapidly increasing form of heart failure.</p>
<div class="lb-trans"><p>该研究在纽约市西奈山医疗中心的动脉血栓研究单位主任、医学/心脏病学教授 Juan J Badimon 博士的指导下进行，名为 “SOTA P CARDIA：无糖尿病 HFpEF 患者的 sotagliflozin 随机试验”，是一项前瞻性、随机、双盲、安慰剂对照试验，专门招募 HFpEF 患者，这是心力衰竭中增长最快的形式。</p>
</div><p>The objective of the study was to compare treatment with sotagliflozin to placebo on a number of cardiac functional and structural measures, such as left ventricular mass, diastolic function, standard six-minute walk test, and KCCQ. The study enrolled 88 participants who were racially diverse and 70 percent female. Patients were treated with sotagliflozin or placebo for six months, and comparisons were made between groups during and after completion of treatment.</p>
<div class="lb-trans"><p>该研究的目的是比较 sotagliflozin 与安慰剂在多个心脏功能和结构指标上的治疗效果，例如左心室质量、舒张功能、标准六分钟步行测试和 KCCQ。研究招募了 88 名参与者，种族多样性，70% 为女性。患者接受 sotagliflozin 或安慰剂治疗六个月，并在治疗期间及结束后进行组间比较。</p>
</div><p>Treatment with sotagliflozin resulted in statistically significant improvements in left ventricular mass, diastolic function, capacity for a six-minute walk test, and KCCQ measurements. In addition, though peak VO2 improvement did not achieve statistical significance, there was a notable improvement after treatment with sotagliflozin.</p>
<div class="lb-trans"><p>sotagliflozin 治疗导致左心室质量、舒张功能、六分钟步行测试能力和 KCCQ 测量的统计学显著改善。此外，尽管峰值 VO2 的改善未达到统计学显著性，但在 sotagliflozin 治疗后有明显改善。</p>
</div><p>“The benefits observed with sotagliflozin treatment in the study include significant improvements in cardiac structure and function, symptom relief and, most importantly, quality of life and functional capacity,” said Dr. Badimon. “Although sotagliflozin was approvedmore than two years ago for heart failurepatients with or withoutdiabetes, our study is the first to demonstrate important clinical benefits for patientswith preserved ejection fraction without diabetes.”</p>
<div class="lb-trans"><p>“在研究中观察到的 sotagliflozin 治疗的益处包括心脏结构和功能的显著改善、症状缓解，以及最重要的生活质量和功能能力的提升，” Badimon 博士表示。“尽管 sotagliflozin 在两年前已获批用于有或无糖尿病的心力衰竭患者，但我们的研究是首个证明对无糖尿病的保留射血分数患者具有重要临床益处的研究。”</p>
</div><p>According to the American College of Cardiology, nearly 6.7 million Americans have heart failure, more than half with preserved ejection fraction. This condition often leads to frequent hospitalizations and has a one-year risk of death of roughly 25 percent.</p>
<div class="lb-trans"><p>根据美国心脏病学会的数据显示，近 670 万美国人患有心力衰竭，其中超过一半为保留射血分数。这种情况通常导致频繁住院，且一年死亡风险约为 25%。</p>
</div><p>“When you combine these study results with previously reported data on reductions among patients treated with sotagliflozin in the risks for MACE and rehospitalization following previous hospitalization for acute heart failure events, the potential for sotagliflozin to be considered a different class of medication starts to come into focus,” said Craig Granowitz, M.D., Ph.D., Lexicon’s senior vice president and chief medical officer.</p>
<div class="lb-trans"><p>“当你将这些研究结果与之前报告的 sotagliflozin 治疗患者在急性心力衰竭事件后再住院和 MACE 风险降低的数据结合起来时，sotagliflozin 被视为一种不同类别药物的潜力开始显现，” Lexicon 的高级副总裁兼首席医学官 Craig Granowitz 博士表示。</p>
</div><p>Click here and search for “SOTA P CARDIA” to access the study abstract.</p>
<div class="lb-trans"><p>点击此处并搜索 “SOTA P CARDIA” 以访问研究摘要。</p>
</div><p><strong>About Sotagliflozin</strong></p>
<div class="lb-trans"><p><strong>关于 Sotagliflozin</strong></p>
</div><p>Discovered using Lexicon’s unique approach to gene science, sotagliflozin is an oral inhibitor of two proteins responsible for glucose regulation known as sodium-glucose cotransporter types 2 and 1 (SGLT2 and SGLT1). SGLT2 is responsible for glucose and sodium reabsorption by the kidney and SGLT1 is responsible for glucose and sodium absorption in the gastrointestinal tract. Sotagliflozin has been studied in multiple patient populations encompassing heart failure, diabetes, and chronic kidney disease in clinical studies involving approximately 20,000 patients. Sotagliflozin is also currently under investigation for another cardiac condition, hypertrophic cardiomyopathy (HCM).</p>
<div class="lb-trans"><p>sotagliflozin 是通过 Lexicon 独特的基因科学方法发现的，是一种口服抑制剂，针对两种负责葡萄糖调节的蛋白质，即钠 - 葡萄糖共转运蛋白 2 型和 1 型（SGLT2 和 SGLT1）。SGLT2 负责肾脏对葡萄糖和钠的重吸收，而 SGLT1 负责胃肠道对葡萄糖和钠的吸收。sotagliflozin 已在多个患者群体中进行研究，包括心力衰竭、糖尿病和慢性肾病，临床研究涉及约 20,000 名患者。sotagliflozin 目前也在研究另一种心脏疾病，肥厚型心肌病（HCM）。</p>
</div><p><strong>About Lexicon Pharmaceuticals</strong></p>
<div class="lb-trans"><p><strong>关于 Lexicon Pharmaceuticals</strong></p>
</div><p>Lexicon is a biopharmaceutical company with a mission of pioneering medicines that transform patients’ lives. Through the Genome5000™ program, Lexicon’s unique genomics target discovery platform, Lexicon scientists studied the role and function of nearly 5,000 genes and identified more than 100 protein targets with significant therapeutic potential in a range of diseases. Through the precise targeting of these proteins, Lexicon is pioneering the discovery and development of innovative medicines to treat disease safely and effectively. Lexicon has a pipeline of promising drug candidates in discovery and clinical and preclinical development in neuropathic pain, HCM, obesity, metabolism and other indications. For additional information, please visit www.lexpharma.com.</p>
<div class="lb-trans"><p>Lexicon 是一家生物制药公司，致力于开创改变患者生活的药物。通过 Genome5000™计划，Lexicon 独特的基因组靶点发现平台，Lexicon 科学家研究了近 5,000 个基因的作用和功能，并识别出 100 多个在多种疾病中具有显著治疗潜力的蛋白质靶点。通过对这些蛋白质的精确靶向，Lexicon 正在开创安全有效治疗疾病的创新药物的发现和开发。Lexicon 在神经性疼痛、HCM、肥胖、代谢及其他适应症方面拥有一系列有前景的药物候选者，处于发现、临床和临床前开发阶段。有关更多信息，请访问 www.lexpharma.com。</p>
</div><p><strong>Safe Harbor Statement</strong></p>
<div class="lb-trans"><p><strong>安全港声明</strong></p>
</div><p><em>This press release contains “forward-looking statements,” including statements relating to Lexicon’s financial position and long-term outlook on its business, including the commercialization of its approved products and the clinical development of, regulatory filings for, and potential therapeutic and commercial potential of sotagliflozin and its other drug candidates. In addition, this press release also contains forward looking statements relating to Lexicon’s growth and future operating results, discovery, development and commercialization of products, strategic alliances and intellectual property, as well as other matters that are not historical facts or information. All forward-looking statements are based on management’s current assumptions and expectations and involve risks, uncertainties and other important factors, specifically including Lexicon’s ability to meet its capital requirements, successfully commercialize its approved products, successfully conduct preclinical and clinical development and obtain necessary regulatory approvals of its other drug candidates on its anticipated timelines, achieve its operational objectives, obtain patent protection for its discoveries and establish strategic alliances, as well as additional factors relating to manufacturing, intellectual property rights, and the therapeutic or commercial value of its approved products and other drug candidates</em> <em>. Any of these risks, uncertainties and other factors may cause Lexicon’s actual results to be materially different from any future results expressed or implied by such forward-looking statements. Information identifying such important factors is contained under “Risk Factors” in Lexicon’s annual report on Form 10-K for the year ended December 31, 2024, as filed with the Securities and Exchange Commission. Lexicon undertakes no obligation to update or revise any such forward-looking statements, whether as a result of new information, future events or otherwise.</em></p>
<div class="lb-trans"><p>本新闻稿包含 “前瞻性声明”，包括与 Lexicon 的财务状况和长期业务前景相关的声明，包括其已批准产品的商业化以及 sotagliflozin 及其其他药物候选者的临床开发、监管申请和潜在治疗及商业潜力。此外，本新闻稿还包含与 Lexicon 的增长和未来运营结果、产品的发现、开发和商业化、战略联盟和知识产权相关的前瞻性声明，以及其他非历史事实或信息的事项。所有前瞻性声明均基于管理层当前的假设和预期，并涉及风险、不确定性和其他重要因素，特别包括 Lexicon 满足其资本需求的能力、成功商业化其已批准产品的能力、成功进行临床前和临床开发并在预期时间内获得其他药物候选者的必要监管批准的能力、实现其运营目标、为其发现获得专利保护以及建立战略联盟的能力，以及与制造、知识产权和其已批准产品及其他药物候选者的治疗或商业价值相关的其他因素。这些风险、不确定性和其他因素可能导致 Lexicon 的实际结果与任何前瞻性声明所表达或暗示的未来结果存在重大差异。识别这些重要因素的信息包含在 Lexicon 截至 2024 年 12 月 31 日的年度报告 Form 10-K 中的 “风险因素” 部分，该报告已提交给证券交易委员会。Lexicon 没有义务更新或修订任何此类前瞻性声明，无论是由于新信息、未来事件还是其他原因。</p>
</div><p><strong>For Investor and Media Inquiries</strong>:</p>
<div class="lb-trans"><p><strong>投资者和媒体咨询</strong>：</p>
</div><p>Lisa DeFrancesco</p>
<div class="lb-trans"><p>Lisa DeFrancesco</p>
</div><p>Lexicon Pharmaceuticals, Inc.</p>
<div class="lb-trans"><p>Lexicon Pharmaceuticals, Inc.</p>
</div><p>lexinvest@lexpharma.com</p>
<div class="lb-trans"><p>lexinvest@lexpharma.com</p>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.globenewswire.com/newsroom/ti/query-bmY9T1RVM01UZzNNeU0zTWpVek1EZ3lJekl3TURNNU5qYz0" alt="" original-src="https://www.globenewswire.com/newsroom/ti?nf=OTU3MTg3MyM3MjUzMDgyIzIwMDM5Njc="/></p>
<p><img src="https://imageproxy.pbkrs.com/https://ml.globenewswire.com/media/ZmM1YzI3ODQtOTI3OS00NDYzLTk4OTEtNTllNjk2ZjFlODliLTEwMTU1NDAtMjAyNS0xMS0wOC1lbg==/tiny/Lexicon-Pharmaceuticals-Inc-.png" alt="" original-src="https://ml.globenewswire.com/media/ZmM1YzI3ODQtOTI3OS00NDYzLTk4OTEtNTllNjk2ZjFlODliLTEwMTU1NDAtMjAyNS0xMS0wOC1lbg==/tiny/Lexicon-Pharmaceuticals-Inc-.png"/></p>

Clinical Data Demonstrating Efficacy of Sotagliflozin in Preserved Ejection Fraction Heart Failure (HFpEF) without Diabetes Presented at American Heart Association (AHA) Annual Scientific Sessions 2025 | LXRX Stock News

在美国心脏协会（AHA）2025 年度科学会议上展示的临床数据显示，Sotagliflozin 在无糖尿病患者中的射血分数保留型心力衰竭（HFpEF）中的疗效 | LXRX 股票新闻